GMTX News and Press, Gemini Therapeutics Inc. From 08/10/22

Gemini Therapeutics ( NASDAQ: GMTX ) is merging with privately held Disc Medicine in an all-stock transaction. The combined company — which will be headquarters in Watertown, Massachusetts — will be named as Disc Medicine Inc. and trade on Nasdaq ...

Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of hematology programs Combined company is expected to have approximately $175 million of cash or cash equivalents at close, including approximately...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

Gemini Therapeutics Inc. (NASDAQ:GMTX) traded at a new 52-week high today of $19.00. So far today approximately 13 million shares have been exchanged, as compared to an average 30-day volume of 431,000 shares. Gemini Therapeutics Inc is a clinical-stage precision medicine company develop...

Gemini Therapeutics press release (NASDAQ:GMTX): FY GAAP EPS of -$1.78 beats by $0.17. As of December 31, 2021, cash and cash equivalents totaled $136.6 million, with approximately 43.2 million shares of common stock outstanding. For further details see: Gemini Therapeutics GAAP EPS of ...

Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021. “As previously announced this year, Gemini Therapeutics has initiated a process to evaluate strategic options to maximize shareholder value that may potentially res...

The clinical-stage biotech, Gemini Therapeutics (GMTX -4.8%) is trading lower for the fourth straight session on Tuesday as the investors react to the company’s recent announcement on leadership and corporate changes. Issuing a statement on Monday, Gemini (NASDAQ:GMTX) said its current...

Gemini Therapeutics (NASDAQ:GMTX) has appointed Georges Gemayel as interim President and CEO. Gemayel, who currently serves as Executive Chair of Gemini, will succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor t...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of...